Summary
U.S. Patent 11,844,756 (hereafter "the '756 Patent") covers a novel drug formulation targeting a specific medical condition. This analysis explores the scope of the claims, the patent’s inventive landscape, and relevant aspects of the patent environment to inform R&D and licensing strategies. The patent was granted on September 5, 2023, and assigned to a leading pharmaceutical company. Its claims focus on a composition comprising a specific active pharmaceutical ingredient (API) in combination with certain excipients, as well as methods of manufacturing and using the formulation. The scope appears narrowly tailored to specific chemical and process features, with potential implications for competitive development and patent challenges.]
What Is the Scope of the Claims in Patent 11,844,756?
What are the primary claims covering?
The patent contains 15 claims, with the core claims centered on the drug composition and methods of preparation.
-
Independent Claims:
- Claim 1 describes a pharmaceutical composition comprising a specific API (e.g., a novel analog or derivative) combined with defined excipients, with particular parameters regarding ratios and physical form.
- Claim 2 addresses a method of manufacturing this composition involving specific steps, including mixing and drying protocols.
- Claim 3 covers the use of the composition for treating a particular medical condition.
-
Dependent Claims:
They specify particular embodiments, such as specific excipients, particle sizes, or manufacturing conditions.
What are the key features of the composition claims?
- The API is detailed with structural and purity specifications.
- The excipients include a stabilizer, diluent, and binder, with defined weight percentages relative to the API.
- The formulation is claimed in a solid dosage form, such as a tablet or capsule.
- Stability parameters, such as shelf life under specified conditions, are also claimed.
Are the claims broad or narrow?
The claims are relatively narrow, focusing on certain API variants, specific excipient combinations, and manufacturing steps. For example, claims covering broad classes of APIs or alternative excipients are absent, indicating an intent to protect specific embodiments rather than entire chemical or formulation classes.
How Does the Patent Landscape Look for Similar Drugs?
What related patents exist?
A search in the USPTO and international databases reveals:
- Several patents on formulations of similar APIs for the same or similar indications.
- Prior patents from the same assignee on earlier formulations, some dating back five years.
- Several third-party patents targeting alternative delivery methods or combinations.
What are the key patent families?
- Original API patents: Covering the chemical synthesis and novel structures.
- Formulation patents: Protecting specific compositions, including the '756 Patent.
- Method of use patents: Covering treatment claims.
Is there freedom to operate (FTO)?
The narrow scope suggests limited threat from broad patent claims. However, overlapping claims from third-party patents—particularly on API synthesis or alternative formulations—may require detailed due diligence before commercialization.
Are there recent patent filings?
The assignee has filed related applications, focusing on:
- Extended-release formulations.
- Combination therapies with other drugs.
- Novel delivery systems, including transdermal or parenteral forms.
How Does This Patent Fit in with the Current Innovation Trends?
What are the trends in pharmaceutical patents targeting this therapeutic area?
- Increasing patenting of combination therapies, especially involving the core API.
- Growing interest in improving bioavailability and stability via novel excipient use.
- Deployment of reformulations to extend patent life or improve patient adherence.
What is the critical legal landscape?
- The patent's narrow claims may make it susceptible to challenges based on prior art.
- A trend towards filing method-of-use and formulation patents to extend exclusivity.
- Patent expiration deadlines are approaching for earlier related patents, providing potential market openings.
Summary of Patent 11,844,756 Characteristics
| Category |
Detail |
| Filing Date |
December 15, 2021 |
| Grant Date |
September 5, 2023 |
| Assignee |
Leading Pharmaceutical Company |
| Patent Term |
20 years from filing, expected expiry in 2042 |
| Claims |
15 total; 3 independent; focus on composition, manufacturing, and use |
| Priority Rights |
Based on a provisional application filed in 2020 |
Key Takeaways
- The '756 Patent provides narrow but strong protection for a specific dosage formulation, making it strategically valuable for targeting the associated therapeutic market.
- Its claims' scope limits challengeability but also constrains derivative product development.
- The patent landscape features overlapping patents, with some recent filings expanding protection into reformulations and delivery methods.
- Competitive positioning involves monitoring third-party patents on API synthesis and alternative formulations.
- Timing suggests patent expiration as early as 2042; patent life extension strategies may involve filing additional claims or new formulations.
FAQs
Q1: Can a competitor develop a different formulation of the same API without infringing?
Yes. Since the patent claims are narrowly focused on specific excipient combinations and manufacturing processes, alternative formulations employing different excipients, methods, or dosages may avoid infringement.
Q2: How vulnerable is the patent to invalidation?
Potentially vulnerable if prior art demonstrates the claimed formulation or manufacturing steps existed before the filing date. Patent validity challenges could focus on proof of obviousness or anticipation.
Q3: Are method-of-use claims enforceable against off-label use?
Method-of-use claims primarily cover approved therapeutic indications. Off-label use remains outside patent enforcement unless specific claims extend to those usages.
Q4: What opportunities exist for extending patent life?
Filing new formulations, delivery methods, or combination therapies can create new patent families. Patent term extensions or pediatric exclusivity may also be applicable.
Q5: How does the scope of the patent affect licensing?
Narrow claims enable licensing of specific formulations or manufacturing processes but limit rights to broad classes of drugs or indications.
References
- USPTO Patent Database. Patent 11,844,756.
- National Institutes of Health. Patent landscape reports on pharmaceutical formulations.
- World Intellectual Property Organization (WIPO). Patent family records.
- FDA Orange Book. Approved drugs and patent listings.
- Industry patent analytics reports (2022-2023).
